Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus. J of Skin 2023, 7 (4), s226. https://doi.org/10.25251/skin.7.supp.226.